JP7469302B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP7469302B2
JP7469302B2 JP2021523667A JP2021523667A JP7469302B2 JP 7469302 B2 JP7469302 B2 JP 7469302B2 JP 2021523667 A JP2021523667 A JP 2021523667A JP 2021523667 A JP2021523667 A JP 2021523667A JP 7469302 B2 JP7469302 B2 JP 7469302B2
Authority
JP
Japan
Prior art keywords
pertussis
toxoid
immunogenic composition
omvs
omv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506347A (ja
JP2022506347A5 (enExample
Inventor
コントルニ，マリオ
ピッツァ，マリアグラツィア
ゾイベルト，アーニャ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2022506347A publication Critical patent/JP2022506347A/ja
Publication of JP2022506347A5 publication Critical patent/JP2022506347A5/ja
Application granted granted Critical
Publication of JP7469302B2 publication Critical patent/JP7469302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021523667A 2018-11-06 2019-11-04 免疫原性組成物 Active JP7469302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204691 2018-11-06
EP18204691.2 2018-11-06
PCT/EP2019/080120 WO2020094580A1 (en) 2018-11-06 2019-11-04 Immunogenic compositions

Publications (3)

Publication Number Publication Date
JP2022506347A JP2022506347A (ja) 2022-01-17
JP2022506347A5 JP2022506347A5 (enExample) 2022-11-08
JP7469302B2 true JP7469302B2 (ja) 2024-04-16

Family

ID=64456746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523667A Active JP7469302B2 (ja) 2018-11-06 2019-11-04 免疫原性組成物

Country Status (14)

Country Link
US (2) US12128094B2 (enExample)
EP (1) EP3876982A1 (enExample)
JP (1) JP7469302B2 (enExample)
KR (1) KR102852282B1 (enExample)
CN (1) CN112996538B (enExample)
AR (1) AR117191A1 (enExample)
AU (1) AU2019376832B2 (enExample)
BR (1) BR112021007668A2 (enExample)
CA (1) CA3117867A1 (enExample)
EA (1) EA202190914A1 (enExample)
IL (1) IL282753B2 (enExample)
MX (1) MX2021005303A (enExample)
SG (1) SG11202103389WA (enExample)
WO (1) WO2020094580A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082379A1 (en) 2020-12-11 2024-03-14 Glaxosmithkline Biologicals Sa Hyper-Blebbing Bacteria
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155294A1 (en) 2013-03-27 2014-10-02 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Vaccines for the prevention of infections with bordetella
JP2016510056A (ja) 2013-03-08 2016-04-04 クルセル ホランド ベー ヴェー 無細胞百日咳ワクチン
JP2016527294A (ja) 2013-08-05 2016-09-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES3018133T3 (en) * 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
BR112014014950B1 (pt) * 2011-12-21 2022-03-29 Bionet-Asia, Co. Ltd Cepa de bordetella pertussis geneticamente modificada, e, métodos para produzir uma cepa de bordetella pertussis modificada e para produzir antígenos de bordetella pertussis
RU2015106791A (ru) * 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
JP2020500552A (ja) * 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
ES2992907T3 (en) 2017-03-13 2024-12-19 Intravacc B V Bordetella vaccines comprising lps with reduced reactogenicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510056A (ja) 2013-03-08 2016-04-04 クルセル ホランド ベー ヴェー 無細胞百日咳ワクチン
WO2014155294A1 (en) 2013-03-27 2014-10-02 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Vaccines for the prevention of infections with bordetella
JP2016527294A (ja) 2013-08-05 2016-09-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROLIN, O. et al.，Infect Immun，2013年，Vol. 82, No. 2，pp. 491-499
SEUBERT, A. et al.，Expert Rev Vaccines，2014年，Vol. 13, No. 10，pp. 1191-1204

Also Published As

Publication number Publication date
AU2019376832B2 (en) 2024-01-25
IL282753A (en) 2021-06-30
CA3117867A1 (en) 2020-05-14
MX2021005303A (es) 2021-07-07
JP2022506347A (ja) 2022-01-17
US20230201325A1 (en) 2023-06-29
US20250049906A1 (en) 2025-02-13
CN112996538B (zh) 2025-07-08
US12128094B2 (en) 2024-10-29
KR102852282B1 (ko) 2025-09-01
IL282753B2 (en) 2025-04-01
AU2019376832A1 (en) 2021-05-13
EA202190914A1 (ru) 2021-08-03
KR20210090646A (ko) 2021-07-20
SG11202103389WA (en) 2021-05-28
EP3876982A1 (en) 2021-09-15
BR112021007668A2 (pt) 2021-07-27
AR117191A1 (es) 2021-07-21
IL282753B1 (en) 2024-12-01
CN112996538A (zh) 2021-06-18
WO2020094580A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
US20250049906A1 (en) Immunogenic compositions
JP5668049B2 (ja) 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
EP2680885B1 (en) Combination vaccines with lower doses of antigen and/or adjuvant
EA016417B1 (ru) Способ получения вакцины
TWI630915B (zh) 無細胞百日咳疫苗
JP6266631B2 (ja) 免疫原性組成物
JP7650871B2 (ja) 免疫原性組成物
EP2934574A1 (en) Conjugates for protecting against diphtheria and/or tetanus
JP2015536929A (ja) スタフィロコッカス・アウレウスｓｄｒｅｃｎａｂドメイン及びワクチン接種のためのその使用
EA045827B1 (ru) Иммуногенные композиции
EA048463B1 (ru) Иммуногенные композиции
WO2023012331A1 (en) Vaccine for equine herpesvirus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240404

R150 Certificate of patent or registration of utility model

Ref document number: 7469302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150